Cogent Biosciences (COGT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Precision Medicinesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-17. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 11.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.83% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- COGT (Cogent Biosciences) — PDUFA date 2026-11-30
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 1 | Current Confirmed in the company's SEC filing |
SEC 8-K filing Filing date: Nov 5, 2026 · ingested Nov 6, 2026 |
| Clinical trials | 4 | Current Updated within the last 14 days |
ClinicalTrials.gov source date not recorded · ingested Nov 17, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 13 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 71.6/100 (grade B):
- FDA decision date (PDUFA): signal score 1.00, weight used 49%, 49.0 points
- Clinical trials: signal score 0.46, weight used 35%, 16.0 points
- Dilution risk: signal score 0.36, weight used 11%, 4.0 points
- Short interest: signal score 0.50, weight used 4%, 2.1 points
- Publications: signal score 0.65, weight used 1%, 0.5 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
- Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
- Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
- Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
- Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
- Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM). — Qual Life Res 2026 Jun 19 PMID 42319518
- hTERT Expression, Regulation, and Prognostic Significance in Pediatric Medulloblastoma. — bioRxiv 2026 May 6 PMID 42146391
- Molecular biology and phase 1 study of GM-CSF and intrathecal trastuzumab in children with recurrent -posterior fossa ependymoma. — Neuro Oncol 2026 Jul 1 PMID 41920921
- DksA inhibitors against intracellular and persistent Salmonella are effective in acute models of infection. — Sci Adv 2026 Mar 20 PMID 41849594
- Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. — Blood Cancer J 2026 Jan 28 PMID 41605897
13 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cogent Biosciences.
Full COGT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.